160 related articles for article (PubMed ID: 31943410)
21. Synthesis and biological evaluation of RGD and isoDGR peptidomimetic-α-amanitin conjugates for tumor-targeting.
Bodero L; López Rivas P; Korsak B; Hechler T; Pahl A; Müller C; Arosio D; Pignataro L; Gennari C; Piarulli U
Beilstein J Org Chem; 2018; 14():407-415. PubMed ID: 29520305
[TBL] [Abstract][Full Text] [Related]
22. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity.
Frochot C; Di Stasio B; Vanderesse R; Belgy MJ; Dodeller M; Guillemin F; Viriot ML; Barberi-Heyob M
Bioorg Chem; 2007 Jun; 35(3):205-20. PubMed ID: 17223161
[TBL] [Abstract][Full Text] [Related]
23. Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jan; 47(3):696-702. PubMed ID: 14736249
[TBL] [Abstract][Full Text] [Related]
24. Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Liang J; Moore RE; Moher ED; Munroe JE; Al-awar RS; Hay DA; Varie DL; Zhang TY; Aikins JA; Martinelli MJ; Shih C; Ray JE; Gibson LL; Vasudevan V; Polin L; White K; Kushner J; Simpson C; Pugh S; Corbett TH
Invest New Drugs; 2005 Jun; 23(3):213-24. PubMed ID: 15868377
[TBL] [Abstract][Full Text] [Related]
25. Comparison of
Kaeopookum P; Petrik M; Summer D; Klinger M; Zhai C; Rangger C; Haubner R; Haas H; Hajduch M; Decristoforo C
Nucl Med Biol; 2019; 78-79():1-10. PubMed ID: 31678781
[TBL] [Abstract][Full Text] [Related]
26. Cryptophycin affinity labels: synthesis and biological activity of a benzophenone analogue of cryptophycin-24.
Vidya R; Eggen M; Georg GI; Himes RH
Bioorg Med Chem Lett; 2003 Feb; 13(4):757-60. PubMed ID: 12639575
[TBL] [Abstract][Full Text] [Related]
27. Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jul; 47(14):3697-9. PubMed ID: 15214797
[TBL] [Abstract][Full Text] [Related]
28. Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
Redko B; Tuchinsky H; Segal T; Tobi D; Luboshits G; Ashur-Fabian O; Pinhasov A; Gerlitz G; Gellerman G
Oncotarget; 2017 Jan; 8(1):757-768. PubMed ID: 27768593
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate.
Raposo Moreira Dias A; Pina A; Dean A; Lerchen HG; Caruso M; Gasparri F; Fraietta I; Troiani S; Arosio D; Belvisi L; Pignataro L; Dal Corso A; Gennari C
Chemistry; 2019 Feb; 25(7):1696-1700. PubMed ID: 30452790
[TBL] [Abstract][Full Text] [Related]
30. Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis.
Nahrwold M; Weiß C; Bogner T; Mertink F; Conradi J; Sammet B; Palmisano R; Royo Gracia S; Preuße T; Sewald N
J Med Chem; 2013 Mar; 56(5):1853-64. PubMed ID: 23387527
[TBL] [Abstract][Full Text] [Related]
31. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.
Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T
Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting α(v)β(3)/α(v)β(5) integrins and IAP proteins.
Mingozzi M; Manzoni L; Arosio D; Dal Corso A; Manzotti M; Innamorati F; Pignataro L; Lecis D; Delia D; Seneci P; Gennari C
Org Biomol Chem; 2014 May; 12(20):3288-302. PubMed ID: 24737345
[TBL] [Abstract][Full Text] [Related]
33. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
[TBL] [Abstract][Full Text] [Related]
34. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
35. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
36. Bifunctional ligands that target cells displaying the alpha v beta3 integrin.
Owen RM; Carlson CB; Xu J; Mowery P; Fasella E; Kiessling LL
Chembiochem; 2007 Jan; 8(1):68-82. PubMed ID: 17154219
[TBL] [Abstract][Full Text] [Related]
37. "Polymultivalent" Polymer-Peptide Cluster Conjugates for an Enhanced Targeting of Cells Expressing α
Duret D; Grassin A; Henry M; Jacquet T; Thoreau F; Denis-Quanquin S; Coll JL; Boturyn D; Favier A; Charreyre MT
Bioconjug Chem; 2017 Sep; 28(9):2241-2245. PubMed ID: 28767233
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes.
Dijkgraaf I; Rijnders AY; Soede A; Dechesne AC; van Esse GW; Brouwer AJ; Corstens FH; Boerman OC; Rijkers DT; Liskamp RM
Org Biomol Chem; 2007 Mar; 5(6):935-44. PubMed ID: 17340009
[TBL] [Abstract][Full Text] [Related]
39. Interaction Mechanism and Clustering among RGD Peptides and Integrins.
Dong X; Yu Y; Wang Q; Xi Y; Liu Y
Mol Inform; 2017 May; 36(5-6):. PubMed ID: 28004516
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
